Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Citi's analysts are advising investors to sell their Moderna shares, citing that the company's revenue and profit forecasts do not justify the significant gains in its stock price, which has risen by over 600%. This recommendation comes as a surprise to some, given the hype surrounding Moderna, particularly in the context of its role in developing COVID-19 vaccines.
The skepticism from Citi's analysts highlights the challenges in evaluating the long-term prospects of companies that have benefited from the pandemic. Moderna's stock has been driven by optimism about its mRNA technology and its potential applications beyond COVID-19. However, the analysts argue that the current share price reflects overly optimistic expectations about the company's future performance. This downgrade could signal a shift in investor sentiment and may lead to increased volatility in Moderna's stock.
Looking ahead, investors will be closely watching Moderna's upcoming earnings reports and updates on its pipeline of new products and technologies. They will also be monitoring the company's progress in diversifying its revenue streams beyond its COVID-19 vaccine. Additionally, the performance of other biotech companies with similar profiles and technologies will be under scrutiny, as it may provide further insight into the sector's prospects and help investors gauge the validity of Citi's concerns about Moderna's valuation.
Originally reported by marketwatch.com. Trade-News adds analysis for finance & markets readers.